NIH and Other Independent Studies Confirm Low Levels of BioAegis' 'Inflammation Regulator Protein,' Gelsolin, Associated with COVID-19 Severity

NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET
| Source:
BioAegis Therapeutics
BioAegis Therapeutics
Morristown, New Jersey, UNITED STATES
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that studies from three independent groups of investigators, including the NIH, have reported
that low levels of gelsolin are associated with severity and organ failure in COVID-19 patients, with the lowest pGSN levels seen in patients who subsequently died. BioAegis is currently conducting a Phase 2 clinical trial of recombinant human plasma gelsolin (rhu-pGSN) in severe COVID-19 patients to supplement gelsolin levels with the objective of preventing severe outcomes such as organ failure and mortality.

Related Keywords

,Steven Cordovano ,Christine Lagana ,National Institute Of Health ,World Health Organization ,Bioaegis Therapeutics Inc ,Clinical Center ,Aegis Therapeutics Inc ,National Institute ,Failure Scores Associated ,Low Gelsolin ,Large Scale Multi Omic Analysis ,Sequential Organ Failure Assessment ,Biomarkers Can Aid ,Clinical Classification ,Host Based Approach ,Bioaegi Phase ,Aegis Is Developing Gelsolin ,Aegis Therapeutics ,கிறிஸ்டின் லகனா ,தேசிய நிறுவனம் ஆஃப் ஆரோக்கியம் ,உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் ,மருத்துவ மையம் ,ஆதரவு சிகிச்சை இன்க் ,தேசிய நிறுவனம் ,தோல்வி மதிப்பெண்கள் தொடர்புடையது ,தொடர்ச்சியான ஆர்கந் தோல்வி மதிப்பீடு ,பயோமார்க்ஸ் முடியும் உதவி ,மருத்துவ வகைப்பாடு ,தொகுப்பாளர் அடிப்படையிலானது அணுகுமுறை ,ஆதரவு சிகிச்சை ,